Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
about
P1343
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyImplications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung CancerA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesPredictive biomarkers in precision medicine and drug development against lung cancerIn vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerMechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung AdenocarcinomaAfatinib for the treatment of metastatic non-small cell lung cancerEpidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Molecular pathways and therapeutic targets in lung cancerEpidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysEstablishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung CancerClinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceβ-catenin contributes to lung tumor development induced by EGFR mutationsA phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR InhibitorsWhacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significanceAssessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer.Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinibCompound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.Resisting Resistance: Targeted Therapies in Lung Cancer.Institutional implementation of clinical tumor profiling on an unselected cancer population.Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
P2860
Q26744284-73BBE79F-801B-4765-A700-394E192DE2C8Q26764917-588DC4AD-9A41-4E21-9BB0-880E8566908AQ26797297-F522A5CD-A82B-497E-A126-FF0BAEEA14ADQ26824536-EEB212CF-8140-486F-97EC-F89C8E3683E8Q27853236-C378B157-BCCF-4E7E-9FA0-FE6343F38209Q28069900-979849B2-47E0-49D2-9ACA-70C926840075Q28082181-8CF872F0-E0FD-49A5-A06B-DDD826CA783CQ30850656-2D943DD2-C8FA-4004-83ED-8D3A418F860AQ33599398-05BCA00B-67B6-49CF-909A-8874F54937CBQ33601653-3A80C475-FCF1-440E-8362-E9C7CF511409Q33688872-DCA42955-3A5F-4D97-9664-DDDA34578119Q33737298-89496D41-9E8A-440F-BE57-9A3FB184F7E7Q33776876-394148F3-401A-4071-9908-F3ECE0313CB1Q34011705-E09C9062-73CF-4FA7-9C99-C982B59CA4A8Q34353437-7C6A7C99-E05D-4FD6-9B04-CCFED003B41DQ35155664-0362ABB4-0B90-41D8-9FAC-57C91868CA97Q35895572-059879E8-3F0B-4203-B21A-BE413FD2D82EQ35896406-AA2F666F-1F8F-4FE4-91AC-BB869461B6A9Q35975657-510E96E5-6559-47EC-9A22-0A1B652AA81BQ36027021-5B729609-7AA2-41C4-AC66-819BFF048807Q36114660-FA29D9D9-8D9B-4AAD-B768-198FE2DE5858Q36116376-E11D2D90-81AC-4184-BD07-15D1571D25B2Q36427381-C2A12F58-100B-465C-9A33-B76082432144Q36493522-62149F9D-C4E4-4412-898B-8031159958FFQ36503084-E564AEE5-C898-475F-B5E3-5E9CDF161A4EQ36511496-AD9716AC-459E-4B23-B39D-E3FAD493F908Q36683851-26F5FE63-52A4-449B-B04A-A9ABF663FEDAQ36728450-BDBE0CDA-7960-4904-B3F3-E88B3DDAA3A8Q36844350-040AEE97-6813-4508-AB91-CD1166F9DC7BQ36927538-2E7A0BF8-1DF6-4053-AF06-692690B339ABQ37060709-8A4161F7-95A0-4ED6-97FE-91A233C3E4D5Q37094986-B10FDBCE-C049-467C-9811-DDE0C097A3A7Q37388238-E6B20A21-83AB-461E-850A-DAC3FB6F659DQ37417570-CD219800-0604-4F05-A476-23C6620F3ED6Q37580410-6B07DD11-3D1E-4145-8BA3-A00F6092B508Q37641681-ACF208C3-9B31-4946-B26A-D4E557CC03EFQ37697306-F6B1DBFE-FF48-4A3B-A44F-468C880CBDEAQ38390205-1CCB2BEC-BBB2-4C53-9063-432A453B56AFQ38584379-870C733C-1F32-4E84-A34F-E2A0AB54E993Q38653663-02652D70-05EA-4324-87D6-818B6415AB47
P2860
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@ast
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@en
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@nl
type
label
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@ast
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@en
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@nl
prefLabel
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@ast
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@en
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@nl
P2093
P2860
P50
P3181
P1476
Structural, Biochemical, and C ...... rtion Mutations in Lung Cancer
@en
P2093
Antonio R Lucena-Araujo
Cai-Hong Yun
Christopher S Lathan
David W Cohen
Eunyoung Park
Geoffrey R Oxnard
Gregory J Riely
Hiroyuki Yasuda
Kota Ishioka
Lecia V Sequist
P2860
P304
P3181
P356
10.1126/SCITRANSLMED.3007205
P407
P4510
P577
2013-12-18T00:00:00Z